InMode Ltd stock (IL0011356806): Nasdaq shares steady as investors look ahead to next earnings update

InMode Ltd shares on Nasdaq traded sideways in recent sessions as investors await the next quarterly earnings release after the Israel-based aesthetic medical device company last reported first-quarter 2026 results in late April.

InMode Ltd shares listed on the Nasdaq in the United States have traded in a relatively tight range in recent sessions, with the stock changing hands around the mid-teens in USD as investors digest the most recent quarterly earnings and await the next financial update from the Israel-based medical technology group. The company, which is headquartered in Yokneam Illit in Israel and whose primary listing is on Nasdaq under the ticker INMD, continues to be followed by U.S. retail and institutional investors as one of the smaller medical device names focused on aesthetics and minimally invasive procedures.

The stock most recently closed in the mid-teens on Nasdaq, reflecting investor expectations after InMode released its first-quarter 2026 results in late April, providing an updated snapshot of revenue trends, margins, and demand for its key platforms across North America and other markets. For German-speaking investors, InMode can also be accessed through trading venues such as Tradegate, where the stock is quoted in EUR based on the underlying Nasdaq line, linking the U.S.-listed shares to investors in Germany and other parts of Europe.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: INMD
• Sector/industry: Medical devices, aesthetic technologies
• Headquarters/country: Yokneam Illit, Israel
• Core markets: North America, Europe, Asia-Pacific, Latin America
• Key revenue drivers: Sales of minimally invasive aesthetic platforms and associated disposables, including body contouring and skin-tightening systems
• Home exchange/listing venue: Nasdaq (INMD)
• Trading currency: USD

InMode Ltd: core business model

InMode operates as a specialized medical technology company that designs and markets minimally invasive and non-invasive aesthetic treatment systems, with revenue primarily generated from selling its capital equipment platforms alongside recurring consumables and service contracts across its global customer base.

Latest quarterly results for InMode Ltd at a glance

InMode last reported its quarterly figures for the first quarter of 2026 in late April, providing the most recent detailed look at the companys operational performance and financial health. According to the firms investor relations materials and filings at that time, management outlined revenue levels compared with the prior-year period, commented on regional demand for its platforms, and updated investors on profitability metrics such as gross margin and operating income for the three-month period ended in early 2026.

Alongside the headline numbers, the first-quarter release also addressed broader trends in InMode's core aesthetic and minimally invasive procedure markets, including commentary on order activity from clinics and practitioners in the United States, Europe, and other geographies. The report further discussed the balance sheet position and cash generation for the quarter, information that helps market participants assess InMode's capacity to fund product development, marketing initiatives, and any potential share repurchase or capital allocation actions through the current financial year.

Conclusion

InMode Ltd shares on Nasdaq are currently reflecting the market's assessment of the first-quarter 2026 results and the outlook for demand in the aesthetic medical device space, with trading volumes and price levels indicating a period of consolidation after the latest report. The most recent earnings release from late April offers investors a reference point on revenue and margin trends, while the upcoming quarters will be important to gauge whether InMode can build on the current platform performance and navigate competitive dynamics in its core markets.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.